CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages.
Conclusion: CPH-I was more valuable than CA125 for differentiating BOT I+II from EOC I+II regardless of menopausal status, while HE4 might be better than CA125 for postmenopausal subgroups. HE4 and CPH-I were more favorable than CA125 for differentiating BOT I+II from EOC I+II in the case of unknown pathology or in serous type.
PMID: 31737130 [PubMed - in process]
Source: Disease Markers - Category: Laboratory Medicine Tags: Dis Markers Source Type: research
More News: Borderline Endometrioid Tumor | Borderline Serous Tumor | Borderline Tumor | Cancer | Cancer & Oncology | Endometrial Cancer | Epithelial Cancer | Laboratory Medicine | Men | Menopause | Ovarian Cancer | Ovaries | Pathology | Study